Company news

Celcuity Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 6, 2025

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

March 31, 2025

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 30, 2025

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

March 24, 2025

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

February 24, 2025

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

December 10, 2024

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

November 13, 2024

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

November 11, 2024

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

November 6, 2024

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

August 13, 2024

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

August 6, 2024

Celcuity To Participate in Jefferies Global Healthcare Conference

June 2, 2024

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

May 29, 2024

Celcuity Announces Pricing of Underwritten Common Stock Offering

May 29, 2024

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

May 14, 2024

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

May 7, 2024

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 26, 2024

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

March 19, 2024

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

March 5, 2024

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

February 27, 2024

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

February 21, 2024

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

February 19, 2024

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

December 5, 2023

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

November 30, 2023

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

November 12, 2023

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

November 5, 2023

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

October 31, 2023

Celcuity Inc. Announces $50 Million Private Placement

October 17, 2023

Celcuity to Host Virtual Science Day for Investors

September 6, 2023

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

August 21, 2023

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

August 21, 2023

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

August 9, 2023

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

August 2, 2023

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

July 30, 2023

Celcuity Set to Join Russell 2000 and 3000 Indexes

June 19, 2023

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

May 23, 2023

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 14, 2023

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

May 11, 2023

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

May 7, 2023

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

May 7, 2023

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

April 17, 2023

Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

April 11, 2023

Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 22, 2023

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

March 15, 2023

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

March 14, 2023

Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

February 28, 2023

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

February 15, 2023

Celcuity Closes $100 Million Private Placement

December 11, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.